During a presentation at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Dr Yuichi Hori and colleagues found that taping the top border of a surgical mask to a clinicians’ skin reduces the potential for ocular surface damage resulting from expirations of air reaching the ocular surface during the COVID-19 pandemic.
The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
Investigators from the New York University Grossman School of Medicine presented data at the ARVO 2022 annual meeting that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Dr Mamoru Ogawa noted that investigators have found that the choroidal and central corneal thicknesses increased over a very short period of time following intensive outdoor activity.
Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.
Non-invasive ocular blood flow measurement using laser speckle flowgraphy may be a new indicator of shock-related organ damage, investigators report.
During a presentation at the ARVO virtual meeting, Lloyd Paul Aiello, MD, PhD, explains that a key hurdle for diabetic retinopathy is the lack of patient awareness, which is a substantial contributor to non-adherence to eye care guidelines and poor outcomes.
During an ARVO presentation, Paul Yang, MD, PhD, explained that in a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.
EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.
Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.
According to Sunil Srivastava, MD, optical coherence tomography characteristics may be predictive of the efficacy of the injections.
During ARVO’s 2021 virtual annual meeting, John Wells, MD, presented efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials.
Bryce Buchowicz, MD, outlines roadblocks to timely diagnosis of central retinal artery occlusion and treatment with tissue plasminogen activator during a virtual presentation at ARVO.
During a presentation at ARVO, Jessica Liu explained that patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.
Investigators review changes in ocular anterior segment blood flow and temperature after treatment of patients with meibomian gland dysfunction.
